Literature DB >> 11155408

A long-term retrospective study of young women with essential thrombocythemia.

A Tefferi1, R Fonseca, D L Pereira, H C Hoagland.   

Abstract

OBJECTIVE: To describe presenting clinical manifestations, long-term disease complications, prognostic indicators, and outcome of pregnancy for women younger than 50 years with essential thrombocythemia. PATIENTS AND METHODS: We retrospectively reviewed the records of all patients with essential thrombocythemia evaluated at Mayo Clinic, Rochester, Minn, between 1969 and 1991 and identified 74 young women (median age, 35 years; range, 18-48 years) with essential thrombocythemia. The diagnosis was based on previously established criteria. Median follow-up was 9.2 years (range, 0.2-26.2 years).
RESULTS: Overall survival was similar to that of an age- and sex-matched control population. Thrombotic events (except superficial thrombophlebitis) occurred at and after diagnosis in 11 patients (15%) and 13 patients (18%), respectively. A history of thrombosis at diagnosis was significantly associated with recurrent thrombosis (P = .03). A platelet count higher than 1500 x 10(9)/L at diagnosis was significantly associated with gastrointestinal tract bleeding and subsequent development of venous (but not arterial) thrombosis (P = .04). Major hemorrhagic events occurred in only 3 patients (4%) after diagnosis. Only 1 patient developed acute leukemia. Thirty-four pregnancies occurred in 18 patients. Of these, 17 (50%) resulted in live births. Of the 17 patients with unsuccessful pregnancies, 14 had spontaneous abortions, 1 had an ectopic pregnancy, and 2 had elective abortions. Preconception platelet count, thrombotic history, or specific therapy was not useful in predicting pregnancy outcome.
CONCLUSION: Young women with essential thrombocythemia can expect long survival with a low incidence of life-threatening thrombohemorrhagic complications or acute leukemia. There is an increased incidence of first-trimester miscarriages that may not be influenced by specific therapy.

Entities:  

Mesh:

Year:  2001        PMID: 11155408     DOI: 10.4065/76.1.22

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  22 in total

1.  Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series.

Authors:  Yan Beauverd; Deepti Radia; Catherine Cargo; Steve Knapper; Mark Drummond; Arvind Pillai; Claire Harrison; Susan Robinson
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

2.  Coronary artery intervention after cytostatics treatment in unstable angina patient with essential thrombocythemia. A case report and literature review.

Authors:  Hyun Chang; Chi Young Shim; June-Won Cheong; Ju-Yeon Pyo; Young Guk Ko; Donghoon Choi; Yangsoo Jang
Journal:  Korean J Intern Med       Date:  2006-06       Impact factor: 2.884

3.  Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.

Authors:  Kazuo Dan; Takashi Yamada; Yukihiko Kimura; Noriko Usui; Shinichirou Okamoto; Takashi Sugihara; Kazue Takai; Michihiko Masuda; Mayumi Mori
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

4.  Cardiac surgery in a patient with essential thrombocythemia: a case report.

Authors:  B E Schölzel; H Endeman; W Dewilde; A Yilmaz; O de Weerdt; J M Ten Berg
Journal:  Neth Heart J       Date:  2010-08       Impact factor: 2.380

5.  How I treat essential thrombocythemia.

Authors:  Philip A Beer; Wendy N Erber; Peter J Campbell; Anthony R Green
Journal:  Blood       Date:  2010-11-24       Impact factor: 22.113

6.  Acute splenic infarction presenting as an unusual manifestation of essential thrombocythaemia with normal platelet count.

Authors:  Katsuyuki Yoshida; Ibuki Kurihara; Takahiko Fukuchi; Hitoshi Sugawara
Journal:  BMJ Case Rep       Date:  2019-07-03

Review 7.  The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.

Authors:  Prajwal Boddu; Lorenzo Falchi; Chitra Hosing; Kate Newberry; Prithviraj Bose; Srdan Verstovsek
Journal:  Leuk Res       Date:  2017-03-22       Impact factor: 3.156

8.  Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

Authors:  Ola Landgren; Lynn R Goldin; Sigurdur Y Kristinsson; Elin A Helgadottir; Jan Samuelsson; Magnus Björkholm
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

Review 9.  Thrombocytosis: too much of a good thing?

Authors:  Andrew I Schafer
Journal:  Trans Am Clin Climatol Assoc       Date:  2002

Review 10.  Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.

Authors:  Raoul Tibes; James M Bogenberger; Kasey L Benson; Ruben A Mesa
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.